Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections; Psoriasis
Intervention: Acitretin (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Hoffmann-La Roche
Summary
To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients.
Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with
psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of
etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in
treating psoriasis in patients without HIV infection by reducing skin involvement and
clearing of the condition, but it has not been thoroughly evaluated in HIV-infected
patients.
Clinical Details
Official title: Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Study design: Treatment, Placebo Control, Efficacy Study
Detailed description:
Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with
psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of
etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in
treating psoriasis in patients without HIV infection by reducing skin involvement and
clearing of the condition, but it has not been thoroughly evaluated in HIV-infected
patients.
Patients receive acitretin daily, with dose increases every 4 weeks based on quantitative
assessment of the skin using the Psoriasis Area and Severity Index (PASI). Treatment
continues for a total of 20 weeks. Patients are followed every 2 weeks.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria
Concurrent Medication:
Allowed:
- Any nondermatologic medication.
Patients must have:
- HIV infection.
- Psoriasis involving at least 10 percent of body surface.
Locations and Contacts
Beth Israel Med Ctr, New York, New York 10003, United States
Additional Information
Last updated: June 23, 2005
|
